2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

US11795164B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Ilona GUTCHER · Berlin, DE
• Norbert Schmees · Berlin, DE
• Lars Röse · Berlin, DE
• Benjamin Bader · Berlin, DE
• Christina KOBER · Lollar, DE
• Rafael CARRETERO · Heidelberg, DE
• Detlef STÖCKIGT · Potsdam, DE
• Horst IRLBACHER · Berlin, DE
• Michael Platten · Heidelberg, DE

Key dates

• Filing date: Aug 12, 2022
• Grant date: Oct 24, 2023
• Expiry date: Aug 12, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.